EUVIMEDEUVIMED entdecken
Crossref

Pretreatment With P2Y12 Inhibitors in ST-Segment Elevation Myocardial Infarction

Miklos Rohla, Shirley Xinyu Ye, Hiroki Shibutani, Jolie Bruno, Tatsuhiko Otsuka, Jonas D Häner, Sarah Bär, Fabrice Temperli, Raminta Kavaliauskaite, Jonas Lanz, Stefan Stortecky, Fabien Praz und 6 weitere

JACC: Cardiovascular Interventions · 2024

DOI: 10.1016/j.jcin.2023.10.064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2024. Verfasst von Miklos Rohla und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Evidence to support immediate P2Y12 inhibitor loading in ST-segment elevation myocardial infarction (STEMI) is limited. OBJECTIVES: This study sought to compare outcomes of STEMI patients receiving immediate or delayed P2Y12 inhibitor treatment. METHODS: Using data from the prospective Bern-PCI registry between 2016 and 2020, we stratified STEMI patients undergoing percutaneous coronary intervention according to time periods with different institutional recommendations regarding P2Y12 inhibitor pretreatment. In cohort 1 (October 2016-September 2018), immediate P2Y12 inhibitor treatment was recommended. In cohort 2 (October 2018-September 2020), P2Y12 inhibitor treatment was recommended after coronary anatomy was confirmed. The primary endpoint was a composite of major adverse cardiac or cerebrovascular events (MACCEs) defined as all-cause death, recurrent myocardial infarction, stroke, or definite stent thrombosis at 30 days. Sensitivity analysis included only patients in whom these recommendations were followed. RESULTS: Cohort 1 included 1,116 patients; pretreatment was actually given in 708 (63.4%). Cohort 2 included 847 patients; pretreatment was withheld in 798 (94.2%). The mean age was 65 ± 13 years, and 24% were female. Baseline characteristics were well-balanced between groups. The median difference for P2Y12 loading to angiography was 52 minutes between cohort 1 and 2 and 100 minutes between patients receiving vs not receiving pretreatment. Rates of MACCEs were similar between cohort 1 and cohort 2 (10.1% vs 8.1%; adjusted HR: 0.91; 95% CI: 0.65-1.28; P = 0.59) and between patients receiving vs not receiving pretreatment (7.1% vs 8.4%; adjusted HR: 1.17; 95% CI: 0.78-1.74; P = 0.45). CONCLUSIONS: In this cohort study of patients with STEMI undergoing primary percutaneous coronary intervention, P2Y12 inhibitor pretreatment was not associated with improved MACCEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionST Elevation Myocardial InfarctionHumansFemaleMiddle AgedAgedMaleCohort StudiesProspective StudiesTreatment OutcomeRegistries

Stichwörter der Autor:innen

P2Y(12) inhibitorsST-elevational myocardial infarctiondual antiplatelet therapy

Autor:innen und Institutionen

  • Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.
  • Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland; Division of Cardiology, Department of Medicine II, Kansai Medical University, Hirakata, Japan.
  • Clinical Trials Unit, University of Bern, Bern, Switzerland.
  • Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland. Electronic address: lorenz.raeber@insel.ch.

Zitieren

APA

Rohla, M., Ye, S. X., Shibutani, H., Bruno, J., Otsuka, T., Häner, J. D., Bär, S., Temperli, F., Kavaliauskaite, R., Lanz, J., Stortecky, S., Praz, F., Hunziker, L., Pilgrim, T., Siontis, G. C., Losdat, S., Windecker, S., & Räber, L. (2024). Pretreatment With P2Y12 Inhibitors in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2023.10.064

Vancouver

Rohla M, Ye SX, Shibutani H, Bruno J, Otsuka T, Häner JD, et al. Pretreatment With P2Y12 Inhibitors in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions. 2024. doi:10.1016/j.jcin.2023.10.064

BibTeX
@article{Rohla2024,
  author = {Rohla, Miklos and Ye, Shirley Xinyu and Shibutani, Hiroki and Bruno, Jolie and Otsuka, Tatsuhiko and Häner, Jonas D and Bär, Sarah and Temperli, Fabrice and Kavaliauskaite, Raminta and Lanz, Jonas and Stortecky, Stefan and Praz, Fabien and Hunziker, Lukas and Pilgrim, Thomas and Siontis, George Cm and Losdat, Sylvain and Windecker, Stephan and Räber, Lorenz},
  title = {Pretreatment With P2Y12 Inhibitors in ST-Segment Elevation Myocardial Infarction},
  journal = {JACC: Cardiovascular Interventions},
  year = {2024},
  doi = {10.1016/j.jcin.2023.10.064}
}
Kostenlos starten →